Role of Simvastatin as an Immunomodulator in Type 2 Diabetes
Open Access
- 1 April 2004
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (4) , 908-913
Abstract
OBJECTIVE—To test the hypothesis that simvastatin reduces the levels of circulating immune complexes (ICs) containing modified lipoproteins (mLDLs; mLDL-ICs), which may represent an additional mechanism for the reduced incidence of cardiovascular events in patients treated with simvastatin. RESEARCH DESIGN AND METHODS—A total of 26 patients with type 2 diabetes and triglyceride levels 1c. RESULTS—Twenty-one patients completed the study. Their HbA1c remained within 1% of baseline levels. There was a highly significant decrease in mLDL-IC levels after 3 and 6 months of treatment with simvastatin, with a return to near baseline levels after discontinuation. CONCLUSIONS—Simvastatin significantly reduced the concentration of mLDL-IC, probably as a consequence of both a decrease in the formation of mLDL and to a reduction in the titers of mLDL antibodies. This effect is likely to have a beneficial impact in the inflammatory reaction associated with atherosclerosis.Keywords
This publication has 27 references indexed in Scilit:
- Autoimmune response to advanced glycosylation end-products of human LDLJournal of Lipid Research, 2003
- The role of immune and inflammatory processes in the development of macrovascular disease in diabetesFrontiers in Bioscience-Landmark, 2003
- Immunochemical Characterization of Purified Human Oxidized Low-Density Lipoprotein AntibodiesClinical Immunology, 2000
- Antibodies to Oxidized LDL and LDL-Containing Immune Complexes as Risk Factors for Coronary Artery Disease in Diabetes MellitusClinical Immunology, 1999
- Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)Diabetes Care, 1997
- Modification of Lipoproteins in DiabetesDiabetes/Metabolism Research and Reviews, 1996
- Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetesBiochemical and Biophysical Research Communications, 1990
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979